Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  Tokyo  >  Chugai Pharmaceutical Co Ltd    4519   JP3519400000

CHUGAI PHARMACEUTICAL CO LTD

(4519)
  Report  
 SummaryChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
Financials (JPY)
Sales 2019 618 B
EBIT 2019 -
Net income 2019 116 B
Finance 2019 234 B
Yield 2019 1,36%
Sales 2020 671 B
EBIT 2020 -
Net income 2020 136 B
Finance 2020 270 B
Yield 2020 1,59%
P/E ratio 2019 33,85
P/E ratio 2020 28,25
EV / Sales2019 6,11x
EV / Sales2020 5,58x
Capitalization 4 013 B
More Financials
Company
Chugai Pharmaceutical Co. specializes in the research, development, manufacturing and marketing of drugs especially for cancers (50.5% of net sales), bones and joints diseases treatment (30.9%), and kidney diseases (7.9%). Net sales are distributed geographically as follows: Japan (81.2%),... 
More about the company
Surperformance© ratings of Chugai Pharmaceutical Co L
Trading Rating : Investor Rating :
More Ratings
Latest news on CHUGAI PHARMACEUTICAL CO L
06/04CHUGAI PHARMACEUTICAL : Files for Additional Indication of ALK Inhibitor ALECENS..
AQ
06/03CHUGAI PHARMACEUTICAL : Final Progression-Free Survival Data and the Second Inte..
BU
05/30CHUGAI PHARMACEUTICAL : Tokyo District Court Renders Judgment on the Patent Infr..
AQ
05/24CHUGAI PHARMACEUTICAL : ponies up $1B+ to combine R&D operations in Yokohama
AQ
05/23CHUGAI PHARMACEUTICAL : Actemra Intravenous Infusion Receives Additional Approva..
AQ
05/22CHUGAI PHARMACEUTICAL : Establishment of Chugai Life Science Park Yokohama and R..
AQ
04/29CHUGAI PHARMACEUTICAL : Notice of Completion of Disposal of Treasury Shares as R..
AQ
04/24CHUGAI PHARMACEUTICAL CO LTD : Slide show Q1 results
CO
04/24CHUGAI PHARMACEUTICAL CO LTD : 1st quarter results
CO
04/19CHUGAI PHARMACEUTICAL : Nemolizumab Shows Positive Results in Maruho's Phase 3 S..
AQ
More news
Analyst Recommendations on CHUGAI PHARMACEUTICAL CO L
More recommendations
Sector news : Pharmaceuticals - NEC
06/18ELANCO ANIMAL HEALTH : China suspending pork imports from third Canadian firm as..
RE
06/18Fosun Eyeing Move for Bayer Animal-Health Business -Bloomberg
DJ
06/18BAYER : Roche wins Japan approval for personalised cancer drug Rozlytrek
RE
06/18ASTRAZENECA : Lynparza gets EU nod as first-line ovarian cancer maintenance trea..
RE
06/18PFIZER : Expands Cancer-Treatment Lineup
DJ
More sector news : Pharmaceuticals - NEC
Chart CHUGAI PHARMACEUTICAL CO LTD
Duration : Period :
Chugai Pharmaceutical Co Ltd Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends CHUGAI PHARMACEUTICAL CO L
Short TermMid-TermLong Term
TrendsBearishNeutralNeutral
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus HOLD
Number of Analysts 10
Average target price 7 280  JPY
Spread / Average Target 1,5%
EPS Revisions
Managers
NameTitle
Tatsuro Kosaka President, CEO & Representative Director
Osamu Nagayama Chairman
Itagaki Toshiaki CFO, Manager-Information Technology & Accounting
Hisafumi Okabe Senior Executive Officer & Head-Research
Hisanori Takanashi Manager-R&D Portfolio Management Department
Sector and Competitors
1st jan.Capitalization (M$)
CHUGAI PHARMACEUTICAL CO LTD12.62%37 224
JOHNSON & JOHNSON8.05%348 981
PFIZER-1.76%233 072
ROCHE HOLDING LTD.14.56%227 848
NOVARTIS23.07%220 893
MERCK AND COMPANY9.02%206 641